Keros Therapeutics, Inc. (KROS) Stock Grade

About Keros Therapeutics, Inc.'s fundamentals

Keros Therapeutics is a biotech company with a market capitalization of $757.8 million that has achieved remarkable revenue growth of 6,775% year-over-year, indicating a significant recent inflection in commercial performance. The company maintains a strong net profit margin of 35.7% and generates a return on equity of 28.7%, suggesting efficient profitability relative to its size and shareholder capital. Trading at a P/E ratio of 8.7, the valuation appears modest relative to earnings, though this reflects the company's early-stage commercial trajectory typical of the biotechnology sector. The company does not currently pay a dividend, which is common for growth-focused biotech firms reinvesting earnings into research and development.